רספרים

Land: Israël

Taal: Hebreeuws

Bron: Ministry of Health

Koop het nu

Werkstoffen:

SULPHAMETHOXAZOLE; TRIMETHOPRIM

Beschikbaar vanaf:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

ATC-code:

J01EE01

farmaceutische vorm:

תרחיף

Samenstelling:

SULPHAMETHOXAZOLE 200 MG / 5 ML; TRIMETHOPRIM 40 MG / 5 ML

Toedieningsweg:

פומי

Prescription-type:

מרשם נדרש

Geproduceerd door:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Therapeutische categorie:

SULFAMETHOXAZOLE AND TRIMETHOPRIM

Therapeutisch gebied:

SULFAMETHOXAZOLE AND TRIMETHOPRIM

therapeutische indicaties:

Treatment of urinary tract infections due to susceptible strains of the following organisms: - Escherichia coli - Klebsiella - Enterobacter - Proteus mirabilis - Proteus vulgaris - Proteus morganii. Treatment of acute otitis media in children due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. To date there are limited data available as to the safety of repeated use of Resprim in infants under 2 years of age. Resprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. Treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei. Resprim is also indicated in the treatment of documented Pneumocystis carinii pneumonitis.

Autorisatie datum:

2012-01-31

Documenten in andere talen

Bijsluiter Bijsluiter Engels 17-08-2016
Productkenmerken Productkenmerken Engels 17-08-2016

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten